Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 11/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19034301 | 1.00 | IDH1 (0.38) | IDH1MAP4K4NPC1MAPTNFKB1 | |
| SCHEMBL16088974 | 0.88 | IDH1 (0.39) | IDH1RAB9ADRD4DRD2DRD3 | |
| SCHEMBL19034296 | 0.88 | IDH1 (0.39) | IDH1RAB9ADRD4DRD2DRD3 | |
| SCHEMBL23957640 | 0.80 | GCG (0.35) | IDH1 | |
| SCHEMBL28938113 | 0.80 | GCG (0.35) | IDH1 | |
| SCHEMBL25563534 | 0.80 | GCG (0.35) | IDH1 | |
| SCHEMBL16044206 | 0.76 | CASR (0.44) | IDH1MAPTNOTUM | |
| SCHEMBL16044973 | 0.76 | CASR (0.44) | IDH1MAPTNOTUM | |
| SCHEMBL16044205 | 0.76 | CASR (0.44) | IDH1MAPTNOTUM | |
| SCHEMBL16044975 | 0.76 | CASR (0.44) | IDH1MAPTNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-02-22 | — | — | US | disclosed |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-02-22 | — | — | US | disclosed |
| EP-2970240-B1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| EP-2970242-B1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-9688672-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9688672-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9434719-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9434719-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-20160039802-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20160039802-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | IDH1 1/4885MAP4K4 2600/4885NPC1 3540/4885 |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | IDH1 1/4885MAP4K4 2600/4885NPC1 3540/4885 |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | IDH1 1/4885MAP4K4 2600/4885NPC1 3540/4885 |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | IDH1 1/4885MAP4K4 2600/4885NPC1 3540/4885 |
| US-20160039802-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3A, IDH3B | IDH1 1/4885MAP4K4 3356/4885NPC1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.